Skip to main content

Quality and Safety

By HIMSS TV | 06:00 am | January 04, 2023
<p>Naomi Fried, PharmStars' founder and CEO, discusses the company's spring 2023 cohort, and its call for applications to digital health groups across the world who focus on women's health and health equity for underserved populations.</p>
By Jeff Lagasse | 07:41 pm | January 03, 2023
The system will be putting $220 million into its newly acquired hospitals with emphasis on provider recruitment and new equipment.
By Susan Morse | 10:53 am | December 29, 2022
The XBB variant, which is resistant to immunity, now makes up over half of cases in New England.
By HIMSS TV | 06:00 am | December 29, 2022
<p>The Translational Research Institute for Space Health's deputy director and chief innovation officer, James Hury, talks about the ways healthcare innovators work with space exploration companies to study astronaut health in order to enhance healthcare on Earth.</p> <p> </p>
By HIMSS TV | 06:00 am | December 28, 2022
<p>The senior data scientist for the Singapore Ministry of Health's Office of Healthcare Transformation, Praveen Deorani, believes that an understanding of people's health engagement is central to getting them to manage their own health.</p>
By HIMSS TV | 06:00 am | December 27, 2022
<p>Voice biomarker technology and machine learning can help assess clinical depression and anxiety in health conversations, explains Grace Chang, cofounder and CEO of Kintsugi.</p> <p> </p>
By Susan Morse | 11:05 am | December 22, 2022
COVID-19 cases have risen 30% in the weeks after Thanksgiving even as RSV trends down the health system says.
By HIMSS TV | 06:00 am | December 22, 2022
<p>Abigail Katz and Leslie Iburg with United Language Group talk about the challenges that come with eventual expiration of the federal public health emergency and what is needed to reach beneficiaries.</p>
By HIMSS TV | 06:00 am | December 21, 2022
<p>Community Health Network is working toward creating seamless and frictionless care delivery. Dr. Patrick McGill, the health system's EVP and chief transformation officer, talks about how and the outcomes.</p>
By Jeff Lagasse | 03:02 pm | December 19, 2022
Overall, 51% of enrolled patients using Adstiladrin therapy achieved a complete response, with all signs of cancer disappearing.